Baricitinib
GET
/api/v1/drug/baricitinibMechanism of action
Sourced from openFDAMechanism-of-action class: Janus Kinase Inhibitors.
Janus Kinase
Approval history
Sourced from openFDA- May 31, 2018NDANDA207924Eli Lilly And Co
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
9,396 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Drug Ineffective7327.8%
- 2Off Label Use6677.1%
- 3Covid-194474.8%
- 4Rheumatoid Arthritis3523.7%
- 5Pulmonary Embolism3023.2%
- 6Pneumonia2742.9%
- 7Headache2612.8%
- 8Herpes Zoster2392.5%
- 9Death2352.5%
- 10Nausea2282.4%
- 11Deep Vein Thrombosis2132.3%
- 12Fatigue1852.0%
- 13Weight Increased1842.0%
- 14Arthralgia1811.9%
- 15Therapy Interrupted1781.9%
Clinical trials
The 10 most recently updated of 191 ClinicalTrials.gov registrations naming Baricitinib as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.Completed · Interventional · 20 enrolled · Benha UniversityNCT07645430updated 2026-06-12
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic DermatitisRecruiting · Phase 1 · Interventional · 20 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)NCT07262983updated 2026-06-12
- Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoCompleted · Phase 2 · Interventional · 49 enrolled · University Hospital, BordeauxNCT04822584updated 2026-06-12
- Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumaticaRecruiting · Phase 3 · Interventional · 140 enrolled · University Hospital, BrestNCT07279688updated 2026-06-10
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior UveitisNot yet recruiting · Phase 3 · Interventional · 33 enrolled · University Hospital, RouenNCT05651880updated 2026-06-08
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)Recruiting · Phase 3 · Interventional · 300 enrolled · Eli Lilly and CompanyNCT07222332updated 2026-06-04
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsRecruiting · Phase 3 · Interventional · 150 enrolled · Eli Lilly and CompanyNCT07222137updated 2026-06-04
- A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase SyndromeRecruiting · Interventional · 80 enrolled · China-Japan Friendship HospitalNCT07406932updated 2026-06-03
- Baricitinib in Patients With Relapsing or naïve DermatomyositisRecruiting · Phase 3 · Interventional · 62 enrolled · Assistance Publique - Hôpitaux de ParisNCT04972760updated 2026-06-02
- Inflammation and Depression in People With HIVRecruiting · Phase 2 · Interventional · 60 enrolled · Emory UniversityNCT05849038updated 2026-05-28
Frequently asked questions
- How does Baricitinib work?
- Mechanism-of-action class: Janus Kinase Inhibitors.
- What class of drug is Baricitinib?
- Baricitinib is classified as Janus-associated kinase (JAK) inhibitors, Janus Kinase Inhibitor, Janus Kinase Inhibitors, Increased Extracellular Communication.
- What are the brand names for Baricitinib?
- Baricitinib is marketed under brand names including Olumiant.
Note. Data for
baricitinib is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.